Notably, deficiency of RNF31 and IPO13 greatly impaired tumour progression upon PTX administration, as indicated by significantly reduced increases in the size and weight of the xenograft tumours (Figure 5B–E). This evidence concerns the gene IPO13 and neoplasm.